Campath^®

Campath^® - The branded name for alemtuzumab, Campath^® (also called Campath-1H) is a type of monoclonal antibody most commonly used in the treatment of B-cell chronic lymphocytic leukemia (CLL). Campath^® is the first and only monoclonal antibody (a laboratory-produced substance designed to locate, bind to, and destroy cancerous cells) currently approved by the FDA for this form of cancer. Campath^® is given by injection either under the skin (subcutaneous) or into a vein (intravenous). While side effects from Campath^® vary, the most common side effects include the following: infection, nausea/vomiting, fever, chills, rashes, and low blood counts (e.g., white blood cells, red blood cells and platelets).

Previous: Bronchoscopy

Next: Cancer

Back to the Cancer Glossary